Nazem Akoum MD , Mario Mekhael MD , Felipe Bisbal MD , Oussama Wazni MD , Christopher McGann MD , Hyejung Lee MS , Tyler Bardsley MS , Tom Greene PhD , J. Michael Dean MD , Lilas Dagher MD , Eugene Kholmovski PhD , Moussa Mansour MD , Francis Marchlinski MD , David Wilber MD , Gerhard Hindricks MD , Christian Mahnkopf MD , Darryl Wells MD , Pierre Jaïs MD , Prashanthan Sanders MD , Johannes Brachmann MD , Nassir Marrouche MD
{"title":"心房颤动导管消融中的病灶输送和瘢痕形成 DECAAF II 试验。","authors":"Nazem Akoum MD , Mario Mekhael MD , Felipe Bisbal MD , Oussama Wazni MD , Christopher McGann MD , Hyejung Lee MS , Tyler Bardsley MS , Tom Greene PhD , J. Michael Dean MD , Lilas Dagher MD , Eugene Kholmovski PhD , Moussa Mansour MD , Francis Marchlinski MD , David Wilber MD , Gerhard Hindricks MD , Christian Mahnkopf MD , Darryl Wells MD , Pierre Jaïs MD , Prashanthan Sanders MD , Johannes Brachmann MD , Nassir Marrouche MD","doi":"10.1016/j.hrthm.2024.08.062","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The Efficacy of Delayed Enhancement MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation of Atrial Fibrillation randomized trial showed no difference in atrial fibrillation (AF) recurrence with additional delayed enhancement magnetic resonance imaging (DE-MRI) fibrosis-targeted ablation to pulmonary vein isolation (PVI) in persistent AF.</div></div><div><h3>Objective</h3><div>We evaluated the effect of lesion delivery on ablation-induced scarring and AF recurrence.</div></div><div><h3>Methods</h3><div>Lesions delivered, targeting fibrotic and nonfibrotic areas identified from preablation DE-MRI, were studied in relation to ablation-induced scarring on 3-month DE-MRI, including their association with arrhythmia recurrence.</div></div><div><h3>Results</h3><div>A total of 593 patients treated with radiofrequency were analyzed: 293 (49.4%) underwent PVI and 300 (50.6%) underwent additional fibrosis-guided ablation. Lesion analysis showed that 80.9% in the MRI fibrosis-guided group vs 16.5% in the PVI group (<em>P</em> < .001) had ≥40% of baseline fibrosis targeted. MRI assessment of ablation-induced scar showed that 44.8% of fibrosis-guided ablation and 15.5% of PVI had ≥40% of their fibrosis covered by scar (<em>P</em> < .001), demonstrating significant attenuation from lesions delivered to scar formed. In the overall population, fibrosis coverage with scar was not associated with recurrence (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.80–1.01; <em>P</em> = .08 per 20% increase). In patients with baseline fibrosis < 20%, fibrosis coverage with scar was associated with lower recurrence than PVI (HR 0.85; 95% CI 0.73–0.97; <em>P</em> = .03), whereas the association was not significant when baseline fibrosis ≥ 20% (HR 0.97; 95% CI 0.80–1.17; <em>P</em> = .77). Significant center variation was observed in fibrosis targeting and coverage with scarring.</div></div><div><h3>Conclusion</h3><div>Radiofrequency ablation lesions do not uniformly result in scar formation. A post hoc analysis suggests reduced arrhythmia recurrence when ablation-induced scarring covers fibrotic regions in patients with low baseline fibrosis.</div></div>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":"22 6","pages":"Pages 1384-1393"},"PeriodicalIF":5.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lesion delivery and scar formation in catheter ablation for atrial fibrillation: The DECAAF II trial\",\"authors\":\"Nazem Akoum MD , Mario Mekhael MD , Felipe Bisbal MD , Oussama Wazni MD , Christopher McGann MD , Hyejung Lee MS , Tyler Bardsley MS , Tom Greene PhD , J. Michael Dean MD , Lilas Dagher MD , Eugene Kholmovski PhD , Moussa Mansour MD , Francis Marchlinski MD , David Wilber MD , Gerhard Hindricks MD , Christian Mahnkopf MD , Darryl Wells MD , Pierre Jaïs MD , Prashanthan Sanders MD , Johannes Brachmann MD , Nassir Marrouche MD\",\"doi\":\"10.1016/j.hrthm.2024.08.062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The Efficacy of Delayed Enhancement MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation of Atrial Fibrillation randomized trial showed no difference in atrial fibrillation (AF) recurrence with additional delayed enhancement magnetic resonance imaging (DE-MRI) fibrosis-targeted ablation to pulmonary vein isolation (PVI) in persistent AF.</div></div><div><h3>Objective</h3><div>We evaluated the effect of lesion delivery on ablation-induced scarring and AF recurrence.</div></div><div><h3>Methods</h3><div>Lesions delivered, targeting fibrotic and nonfibrotic areas identified from preablation DE-MRI, were studied in relation to ablation-induced scarring on 3-month DE-MRI, including their association with arrhythmia recurrence.</div></div><div><h3>Results</h3><div>A total of 593 patients treated with radiofrequency were analyzed: 293 (49.4%) underwent PVI and 300 (50.6%) underwent additional fibrosis-guided ablation. Lesion analysis showed that 80.9% in the MRI fibrosis-guided group vs 16.5% in the PVI group (<em>P</em> < .001) had ≥40% of baseline fibrosis targeted. MRI assessment of ablation-induced scar showed that 44.8% of fibrosis-guided ablation and 15.5% of PVI had ≥40% of their fibrosis covered by scar (<em>P</em> < .001), demonstrating significant attenuation from lesions delivered to scar formed. In the overall population, fibrosis coverage with scar was not associated with recurrence (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.80–1.01; <em>P</em> = .08 per 20% increase). In patients with baseline fibrosis < 20%, fibrosis coverage with scar was associated with lower recurrence than PVI (HR 0.85; 95% CI 0.73–0.97; <em>P</em> = .03), whereas the association was not significant when baseline fibrosis ≥ 20% (HR 0.97; 95% CI 0.80–1.17; <em>P</em> = .77). Significant center variation was observed in fibrosis targeting and coverage with scarring.</div></div><div><h3>Conclusion</h3><div>Radiofrequency ablation lesions do not uniformly result in scar formation. A post hoc analysis suggests reduced arrhythmia recurrence when ablation-induced scarring covers fibrotic regions in patients with low baseline fibrosis.</div></div>\",\"PeriodicalId\":12886,\"journal\":{\"name\":\"Heart rhythm\",\"volume\":\"22 6\",\"pages\":\"Pages 1384-1393\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heart rhythm\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1547527124032880\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart rhythm","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1547527124032880","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Lesion delivery and scar formation in catheter ablation for atrial fibrillation: The DECAAF II trial
Background
The Efficacy of Delayed Enhancement MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation of Atrial Fibrillation randomized trial showed no difference in atrial fibrillation (AF) recurrence with additional delayed enhancement magnetic resonance imaging (DE-MRI) fibrosis-targeted ablation to pulmonary vein isolation (PVI) in persistent AF.
Objective
We evaluated the effect of lesion delivery on ablation-induced scarring and AF recurrence.
Methods
Lesions delivered, targeting fibrotic and nonfibrotic areas identified from preablation DE-MRI, were studied in relation to ablation-induced scarring on 3-month DE-MRI, including their association with arrhythmia recurrence.
Results
A total of 593 patients treated with radiofrequency were analyzed: 293 (49.4%) underwent PVI and 300 (50.6%) underwent additional fibrosis-guided ablation. Lesion analysis showed that 80.9% in the MRI fibrosis-guided group vs 16.5% in the PVI group (P < .001) had ≥40% of baseline fibrosis targeted. MRI assessment of ablation-induced scar showed that 44.8% of fibrosis-guided ablation and 15.5% of PVI had ≥40% of their fibrosis covered by scar (P < .001), demonstrating significant attenuation from lesions delivered to scar formed. In the overall population, fibrosis coverage with scar was not associated with recurrence (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.80–1.01; P = .08 per 20% increase). In patients with baseline fibrosis < 20%, fibrosis coverage with scar was associated with lower recurrence than PVI (HR 0.85; 95% CI 0.73–0.97; P = .03), whereas the association was not significant when baseline fibrosis ≥ 20% (HR 0.97; 95% CI 0.80–1.17; P = .77). Significant center variation was observed in fibrosis targeting and coverage with scarring.
Conclusion
Radiofrequency ablation lesions do not uniformly result in scar formation. A post hoc analysis suggests reduced arrhythmia recurrence when ablation-induced scarring covers fibrotic regions in patients with low baseline fibrosis.
期刊介绍：
HeartRhythm, the official Journal of the Heart Rhythm Society and the Cardiac Electrophysiology Society, is a unique journal for fundamental discovery and clinical applicability.
HeartRhythm integrates the entire cardiac electrophysiology (EP) community from basic and clinical academic researchers, private practitioners, engineers, allied professionals, industry, and trainees, all of whom are vital and interdependent members of our EP community.
The Heart Rhythm Society is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal health care policies and standards.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
